Advanced search
Publication Cover
Patient Preference and Adherence Volume 17, 2023 - Issue
Submit an article Journal homepage
198
Views
1
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Evolution of the RebiSmart® Electromechanical Autoinjector to Improve Usability in Support of Adherence to Subcutaneous Interferon Beta-1a Therapy for People Living with Multiple Sclerosis

Yu-Ting Lin1 Device and Connected Solution Engineering, Global Healthcare Operations, Ares Trading SA (an affiliate of Merck KGaA), Eysins, SwitzerlandCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-5238-3208View further author information
ORCID Icon,
Tamara Will2 Human Factors Research & Design, Emergo by UL, Utrecht, the NetherlandsORCID Iconhttps://orcid.org/0000-0003-1079-8362View further author information
ORCID Icon,
Charlotte Wickham3 Human Factors Research & Design, Emergo by UL, Cambridge, UKORCID Iconhttps://orcid.org/0009-0009-9092-017XView further author information
ORCID Icon,
Petra Boeree2 Human Factors Research & Design, Emergo by UL, Utrecht, the NetherlandsORCID Iconhttps://orcid.org/0000-0002-4738-3251View further author information
ORCID Icon,
Dominic Jack4 Medical Unit Neurology & Immunology, Global Research & Development, Merck Serono Ltd (an affiliate of Merck KGaA), Feltham, UKORCID Iconhttps://orcid.org/0000-0001-8629-553XView further author information
ORCID Icon &
Matthew Keiser1 Device and Connected Solution Engineering, Global Healthcare Operations, Ares Trading SA (an affiliate of Merck KGaA), Eysins, Switzerland;5 Device and Connected Solution Engineering, Global Healthcare Operations, EMD Serono, Inc (an affiliate of Merck KGaA), Rockland, MA, USAORCID Iconhttps://orcid.org/0000-0001-6870-6585View further author information
ORCID Icon
Pages 1923-1933 | Received 13 Apr 2023, Accepted 28 Jul 2023, Published online: 09 Aug 2023

References

  • Steinberg SC, Faris RJ, Chang CF, Chan A, Tankersley MA. Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Investig. 2010;30(2):89–100. doi:10.2165/11533330-000000000-00000
  • Lugaresi A, Florio C, Brescia-Morra V, et al. Patient adherence to and tolerability of self-administered interferon beta-1a using an electronic autoinjection device: a multicentre, open-label, Phase IV study. BMC Neurol. 2012;12:7. doi:10.1186/1471-2377-12-7
  • Bayas A, Ouallet JC, Kallmann B, Hupperts R, Fulda U, Marhardt K. Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study. Expert Opin Drug Deliv. 2015;12(8):1239–1250. doi:10.1517/17425247.2015.1057567
  • Valis M, Sarlakova J, Haluskova S, et al. An observational study demonstrating the adherence and ease of use of the injector device, RebiSmart. Expert Opin Drug Deliv. 2020;17(5):719–724. doi:10.1080/17425247.2020.1742694
  • Pavelek Z, Novotny M, Klimova B, et al. DORADA adherence study: full view into RebiSmart subdomains parameters in multiple sclerosis treatment. Curr Med Res Opin. 2021;37(4):589–596. doi:10.1080/03007995.2021.1880886
  • Edo Solsona MD, Monte Boquet E, Casanova Estruch B, Poveda Andres JL. Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by RebiSmart in patients with multiple sclerosis. Patient Prefer Adherence. 2017;11:415–421. doi:10.2147/PPA.S127508
  • Lugaresi A, De Robertis F, Clerico M, et al. Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon beta-1a using an electronic device: the RIVER study. Expert Opin Drug Deliv. 2016;13(7):931–935. doi:10.1517/17425247.2016.1148029
  • Willis H, Webster J, Larkin AM, Parkes L. An observational, retrospective, UK and Ireland audit of patient adherence to subcutaneous interferon beta-1a injections using the RebiSmart injection device. Patient Prefer Adherence. 2014;8:843–851. doi:10.2147/PPA.S54986
  • Devonshire VA, Feinstein A, Moriarty P. Adherence to interferon beta-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study. BMC Res Notes. 2016;9:148. doi:10.1186/s13104-016-1948-z
  • Krol M, de Voer G, Osowski U. Patient adherence to subcutaneous IFN beta-1a injections using the RebiSmart injection device: a retrospective real-world study among Dutch and German patients with multiple sclerosis. Patient Prefer Adherence. 2017;11:1189–1196. doi:10.2147/PPA.S130985
  • Pedersen ED, Stenager E, Vadgaard JL, et al. Adherence to subcutaneous interferon beta-1a treatment using an electronic injection device: a prospective open-label Scandinavian noninterventional study (the ScanSmart study). Patient Prefer Adherence. 2018;12:569–575. doi:10.2147/PPA.S154417
  • Rieckmann P, Ziemssen T, Penner IK, et al. Adherence to subcutaneous interferon beta-1a in multiple sclerosis patients receiving periodic feedback on drug use by discussion of readouts of their RebiSmartinjector: results of the prospective cohort study REBIFLECT. Adv Ther. 2022;39(6):2749–2760. doi:10.1007/s12325-022-02100-w

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.